• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Abu Dhabi Department of Health Forms Strategic Partnership with M42, AbbVie


Collaboration to focus on personalized medicine in the United Arab Emirates capital.

3d illustration of a cancer cell and lymphocytes. Image Credit: Adobe Stock Images/Christopher Burgstedt

Image Credit: Adobe Stock Images/Christopher Burgstedt

The Department of Health – Abu Dhabi, the governing board of healthcare in the United Arab Emirates (UAE), announced an agreement with AbbVie Biopharmaceutical and M42, an integrated healthcare company, in an effort to mold personalized medicine genomics within the city. As part of the partnership, the three parties intend to advance the diagnosis and treatment of multiple myeloma and non-small cell lung cancer.

"This partnership aims to advance precision medicine in the diagnosis and treatment to help enable broader patient access in UAE to innovative therapies,” said Hassan Sabbah, general manager, AbbVie Gulf & Levant. “Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges, and burdens."

Reference: Department of Health - Abu Dhabi, M42 and AbbVie enter a strategic partnership to advance personalised medicine and genomics. June 19, 2023. Accessed June 21, 2023. https://www.prnewswire.com/news-releases/department-of-health--abu-dhabi-m42-and-abbvie-enter-a-strategic-partnership-to-advance-personalised-medicine-and-genomics-301854543.html

Recent Videos
Related Content